You are here

News

subscribe

The latest international news, analysis and features on the HIV epidemic from Avert. Share your views and expertise with your peers in the comments box below the articles.

23 July 2020

Injectable PrEP – an exciting tool, but no silver bullet for adherence

We talk to Giffin Daughtridge, CEO of medical diagnostics company, UrSure, about treatment adherence and the impact of long-acting cabotegravir as injectable PrEP.

07 July 2020

Africa hailed for HIV success, but unequal progress means targets will be missed

The 23rd International AIDS Conference (AIDS 2020 Virtual) kicked-off with a clear message from UNAIDS to accelerate efforts to end AIDS and not be derailed by COVID-19.

01 July 2020

HIV testing in South Africa rises by 45% in 12 years

The proportion of South Africans ever testing for HIV increased from 30% to 75% between 2005 and 2017 – but differences remain in who is getting tested

05 May 2020

China: rapid rise in drug-resistant HIV among people not previously on treatment

HIV drug resistance among treatment-naïve people in China rising rapidly from 2012 and tops 10% in Central China.

03 February 2020

5 things you need to know about Boost

We have launched a new mobile app made in collaboration with community health workers in Southern Africa. Find out all you need to know about Boost!

29 January 2020

Targeted testing in Botswana increases HIV diagnoses by 77% among young people and 37% among men

Mobile testing and door-to-door approaches result in a 25% increase in status awareness, with particularly significant gains in diagnosing HIV-positive young people and men.

23 January 2020

Less isolated, less fearful: peer-led programme for HIV-positive adolescents has significant impact

An evaluation of Zvandiri, a teen-led programme for HIV-positive adolescents in Zimbabwe, finds it significantly improves treatment outcomes and boosts self-esteem.

17 January 2020

HIV infections continue to fall in UK thanks to testing and treatment

UK efforts to end the HIV epidemic by 2030 are advancing, but challenges remain around reaching those undiagnosed and those diagnosed late.